Avacta Therapeutics Presents Preclinical and Translational Data from pre
LONDON and PHILADELPHIA, April 28, 2025 (GLOBE NEWSWIRE) -- Avacta Therapeutics (AIM: AVCT), a life sciences company developing next generation peptide drug conjugates (PDC) targeting powerful anti-tumor payloads directly to the tumor, today announced preclinical results from its second pre|CISION® candidate FAP-EXd (AVA6103) and new analyses around the potential of the pre|CISION® platform at the American Association for Cancer Research (AACR) Annual Meeting in Chicago, IL.
The pre|CISION® programs are designed to target fibroblast activation protein-alpha (FAPα), the protease that forms the basis of the platform. FAP is consistently overexpressed across a broad range of solid tumors and enriched at the tumor-stroma interface, making it an ideal target for tumor-localized drug activation. Avacta's proprietary pre|CISION® chemistry leverages this tumor-specific biology to activate potent drugs selectively at the tumor site, enhancing efficacy while minimizing systemic toxicity.
"The encouraging results we are showcasing at this year's AACR Annual Meeting highlight the versatility of our pre|CISION® platform,' said Michelle Morrow, CSO of Avacta Therapeutics. 'Our data presented today demonstrate that the platform can deliver potent payloads like exatecan with remarkable tumor selectivity and our novel sustained release mechanism. Together, these programs reinforce the broad potential of our pipeline to transform outcomes for patients and generate long-term value for shareholders.'
AVA6103 (FAP-EXd) Preclinical Candidate Highlights (Abstract 3139, 28 April 2025)
Avacta presented preclinical data from its second clinical candidate, AVA6103, a novel FAP-activated pre|CISION® PDC delivering the topoisomerase I inhibitor exatecan directly to the tumor-stroma interface. This mechanism minimizes systemic toxicity while ensuring precise delivery of the cytotoxic agent directly to the tumor with a sustained release mechanism that optimizes the pharmacokinetics of the released payload. Importantly, despite a very short half-life of 9 hours with conventional exatecan, FAP-EXd (AVA6103) is capable of delivering high tumor concentration vs. plasma with exposures of more than 60 hours projected with a single dose. Additionally, FAP-EXd's bystander effect enables exatecan to induce cytotoxicity in surrounding FAP-negative cancer cells, enhancing its therapeutic impact.
The compound has demonstrated significant tumor growth inhibition and durable complete responses in multiple patient-derived xenograft models, including those that are resistant to topoisomerase I inhibition. These results reinforce the potential of FAP-EXd to deliver effective, targeted treatment with minimal off-target effects. The investigational new drug (IND) submission is anticipated in December 2025 and initiation of the first-in-human study in the first quarter of 2026.
Abstract Number and Title: #3139: The novel PDC AVA6103 is a FAP-enabled pre|CISION® medicine which targets exatecan, a topoisomerase I inhibitor, to the tumor microenvironment following FAP cleavage· Session Category: Experimental and Molecular Therapeutics· Session Title: Therapeutic Approach to Attack the Tumor Microenvironment· Session Date and Time: Monday, April 28, 2025, 2:00 - 5:00 p.m. CT
FAP Targeting Approach with pre|CISION® medicines (Abstract 2699, 28 April 2025)
FAP is overexpressed across a wide range of solid tumors, with estimated frequency of over 90% of patients with evidence of FAP expression. This expression is spatially enriched at the tumor-stroma interface, demonstrating the effective nature of the pre|CISION® mechanism to deliver highly potent payloads directly to the tumor. Given the broad expression of FAP in human solid tumors and correlation of the protein and RNA levels of FAP, an AI-based approach to this target was employed with the Avacta strategic collaboration with Tempus.
Avacta's work with Tempus has demonstrated several key aspects of the pre|CISION® platform, namely (1) FAP expression remains consistent across lines of therapy and in pre- and post-tumor samples, and (2) co-expression of genes associated with sensitivity to the payload and FAP identify the optimal patient populations for pre|CISION® medicines including FAP-EXd. These data reinforce the potential of Avacta's pre|CISION® platform to deliver potent therapies across multiple solid tumor indications with broad clinical utility.
Abstract Number and Title: #2699: Investigating fibroblast activation protein alpha (FAPα) as a therapeutic target for delivery of pre|CISION® cancer medicines: Expression, spatial localization and functional insights· Session Category: Tumor Biology· Session Title: Targeting the Tumor Microenvironment: A Brave New World· Session Date and Time: Monday, April 28, 2025, 2:00 - 5:00 p.m. CT
For further information from Avacta, please contact:
Avacta Group plcMichael Vinegrad, Group CommunicationsDirector
avacta.com
Peel Hunt (Nomad and Broker)James Steel / Chris Golden
www.peelhunt.com
Panmure Liberum (Joint Broker)Emma Earl / Will Goode / Mark Rogers
www.panmureliberum.com
ICR HealthcareMary-Jane Elliott / Jessica Hodgson / Stephanie Cuthbert
avacta@icrhealthcare.com
Investor ContactRenee Leck THRUST Strategic Communications
renee@thrustsc.com
Media ContactCarly ScadutoCarly Scaduto Consulting
Carly@carlyscadutoconsulting.com
About Avacta - avacta.com
Avacta Therapeutics is a clinical-stage life sciences company expanding the reach of highly potent cancer therapies with the pre|CISION® platform. pre|CISION® is a proprietary warhead delivery system based on a tumor-specific protease (fibroblast activation protein or FAP) that is designed to concentrate highly potent warheads in the tumor microenvironment while sparing normal tissues. Our innovative pipeline consists of pre|CISION® peptide drug conjugates (PDC) or Affimer® drug conjugates (AffDC) that leverage the tumor-specific release mechanism, providing unique benefits over traditional antibody drug conjugates.
About the pre|CISION® PlatformThe pre|CISION® platform comprises an anticancer payload conjugated to a proprietary peptide that is a highly specific substrate for fibroblast activation protein (FAP) which is upregulated in most solid tumors compared with healthy tissues. The pre|CISION® platform harnesses this tumor specific protease to cleave pre|CISION® peptide drug conjugates and pre|CISION® antibody/Affimer® drug conjugates in the tumor microenvironment, thus releasing active payload in the tumor and reducing systemic exposure and toxicity, allowing dosing to be optimized to deliver the best outcomes for patients.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Wire
19 minutes ago
- Business Wire
Euna Solutions' 2025 State of Public Procurement Report Finds Budgets Flat, Costs Up, and Teams Pushed to the Brink by Last-Minute Requests
ATLANTA & TORONTO--(BUSINESS WIRE)-- Euna Solutions®, a leading provider of purpose-built, cloud-based solutions for the public sector, today announced the release of its 2025 State of Public Procurement Report. It offers a comprehensive look into how public procurement professionals across North America are confronting economic volatility, budget constraints, and rising stakeholder demands by leveraging technology, streamlining operations, and reimagining their roles as strategic leaders. 'This year's report makes clear that procurement teams are not just managing spend, they're becoming strategic stewards of public trust in a time of economic uncertainty,' said Tom Amburgey, CEO of Euna Solutions. 'This year's report makes clear that procurement teams are not just managing spend, they're becoming strategic stewards of public trust in a time of economic uncertainty,' said Tom Amburgey, CEO of Euna Solutions. 'This year's State of Public Procurement Report shows that with the right tools, even small teams can drive outsized impact. As automation and AI reshape what's possible, Euna is committed to helping public agencies modernize procurement in a way that's not only efficient, but intelligent, equitable, and future-ready.' Based on survey responses from 86 public procurement professionals and 252 suppliers, along with anonymized data from over 3,000 procurement teams using Euna Procurement, the 2025 State of Public Procurement Report reveals a sector that is at a critical inflection point. Despite flat budgets, public procurement teams face shrinking purchasing power due to inflation and rising costs, with 2025 emerging as a pivotal year for transformation. The report's key findings include: Rising Costs Are Undermining Stable Budgets: Although most agencies report that their budgets have remained steady year over year, procurement professionals consistently identified rising costs as their top external challenge. More than 50% of survey respondents flagged inflation and market volatility as a critical constraint; these factors are eroding real purchasing power, making it harder for teams to achieve the same outcomes with the same dollars. Small Teams Face Big Demands: Many public procurement departments consist of just one to three individuals, often tasked with managing the full-cycle procurement process across multiple departments. Complex projects can take upwards of 130 hours without streamlined workflows, highlighting the need for automation and digital transformation. Manual Processes Are Slowing Progress: Outdated systems and fragmented workflows contribute to inefficiencies. Teams spend significant time on routine tasks, limiting their ability to focus on strategy and supplier relationships. Technology Adoption Is Accelerating but Barriers Remain: Nearly 70% of survey respondents have established or plan to establish contract lifecycle management software in the next year, while agencies are also prioritizing investments in supplier performance tracking and invoice automation. However, budget limitations remain the biggest barrier to adopting modern procurement solutions. Digital Tools Drive Real Savings: Procurement teams using Euna Procurement save an average of nearly $35,000 per project through more efficient sourcing, contracting, and supplier engagement. Euna's AI-powered savings advisor has saved agencies over $4.5M through cart optimization at checkout. Full-cycle automation also leads to faster contract execution, reduced late payments, and improved compliance. AI Adoption Slow but Emerging in State Operations: According to the National Association of State Procurement Officials (NASPO), 42% of states now have official AI policies, and all 54 U.S. chief procurement officers included in the polling named AI as a key priority for 2025. While adoption is early, practical use cases are already demonstrating value, such as AI-enabled invoice analysis that flags payment discrepancies before they become costly errors and marketplace tools that rapidly analyze and compare goods for best-value purchasing decisions at scale. Euna's AI-driven procurement solutions alone saved public agencies $1.25M in 2024 and flagged more than 75,000 invoice discrepancies, underscoring the technology's potential to deliver meaningful cost and time savings. The themes within the 2025 State of Public Procurement Report, especially the trend toward automation, full-cycle digital workflows, and data-driven decision-making, point the way toward AI's growing role in the future of public procurement. 'AI is poised to play a pivotal role in public procurement by automating difficult tasks and enabling faster, more strategic decision-making based on real-time data and performance trends,' said Amburgey. 'The foundations being laid today with automation and modern cloud-based platforms are paving the way for intelligent systems that can help procurement teams do even more with their limited resources.' To read the full 2025 State of Public Procurement Report visit: About Euna Solutions Euna Solutions® is a leading provider of purpose-built, cloud-based software that helps public sector and government organizations streamline procurement, budgeting, payments, grants management, and special education administration. Designed to enhance efficiency, collaboration, and compliance, Euna Solutions supports more than 3,400 organizations across North America in building trust, enabling transparency, and driving community impact. Recognized on Government Technology's GovTech 100 list, Euna Solutions is committed to advancing public sector progress through innovative SaaS solutions. To learn more, visit
Business Wire
19 minutes ago
- Business Wire
loanDepot Adds Mortgage Technology Trailblazers to Executive Team
IRVINE, Calif.--(BUSINESS WIRE)--loanDepot, Inc. (NYSE: LDI) (together with its subsidiaries, "loanDepot" or the "Company") today announced two executive appointments intended to drive profitable growth and operating leverage through the development of best-in-class technology. As Chief Digital Officer, Dominick Marchetti leads the Company's overall digital transformation and strategy, ultimately responsible for using technology to drive improved operational outcomes and competitive advantage. As Chief Innovation Officer, Sean DeJulia is responsible for driving innovation throughout the loan manufacturing process across all of its production channels, with a strong focus on the top of the funnel. 'The return of these two brilliant and proven technology trailblazers—each with their own unique but complementary strengths—marks a pivotal moment for the Company and a return to our roots of innovation." Share Said CEO Anthony Hsieh, 'The return of these two brilliant and proven technology trailblazers—each with their own unique but complementary strengths—marks a pivotal moment for the Company and a return to our roots of innovation. I had the privilege of working closely with both as we built the groundbreaking technology that defined loanDepot's early reputation and growth, so I know firsthand what they're capable of. Their return is more than a reunion: it's a force multiplier that will accelerate our digital transformation in both the near and long term. I couldn't be more excited to work with both of them again.' About Dom Marchetti Marchetti, who served as loanDepot's Chief Technology Officer from 2015 to 2019 and is regarded as one of the top mortgage technology leaders in the country, has spent most of his career building and redefining the way mortgage companies do business. He is also a serial entrepreneur who founded his first mortgage company in 1996. After loanDepot, Marchetti joined Rate to help drive its product innovation initiatives before launching his own mortgage tech strategy and consulting firm, Mezzo. At Mezzo he worked closely with many of the industry's top lenders, building new products by leveraging industry experts and developing a deep understanding of the competitive landscape. Said Hsieh, 'Dom is an exceptional partner—someone I trust deeply, who has a proven track record of delivering next-generation capabilities, and with whom I am completely aligned in how we think about the business. Among the many things that set him apart are his expansive knowledge, his incredible industry relationships, and his ability to harness technology and innovation to build and run an exceptional mortgage business.' Said Marchetti, 'The rapid acceleration of AI is bringing significant changes to our industry, and this is an exciting moment to join a leadership team with the knowledge, longevity and vision to embrace those opportunities. Further, the launch of the mello® platform was one of the most rewarding experiences of my career, so I am thrilled to be back at loanDepot working alongside Anthony and the rest of the leadership team to build on our strengths as we harness our technology prowess to drive stronger business outcomes.' About Sean DeJulia DeJulia is a seasoned mortgage technology innovator who started his career with Empower (now Dark Matter Technologies) and honed his software engineering expertise over a decade at loanDepot. After loanDepot, he founded Lodasoft, which works with top mortgage lenders to streamline manufacturing workflows, improve operational efficiency, and reduce both cost and risk for its clients. That experience helped him gain a comprehensive perspective on the industry. In addition, DeJulia brings real-world lending experience to his work. As a mortgage originator, he gained invaluable insights into both loan origination and processing challenges as well as the customer experience, all of which inform his development of intuitive, compliant, and scalable solutions. Said Hsieh, 'There are very few people who match the type of 'mortgage IQ' Sean has, namely deep competitive knowledge and big picture thinking combined with top tier coding talent and first-hand experience as an originator. This is evident not only in his past experience with our Company, but also by his success as an entrepreneur. Sean will set the gold standard for innovation both here at loanDepot and across the mortgage industry.' Said DeJulia, 'The opportunity to return to loanDepot and apply all that I've learned over the course of my career was something I just couldn't pass up. I'm ready to roll up my sleeves and get to work, and I look forward to a strong partnership with Anthony and the entire leadership team as we work to accelerate our growth goals, regain our market share and return to our heritage as a true mortgage innovator.' As part of their charter for the next 90 days, Marchetti and DeJulia will evaluate the critical resources required to develop next generation tools and capabilities. Forward Looking Statements This press release may contain "forward-looking statements," which reflect loanDepot's current views with respect to, among other things, our executive leader capabilities and value, our digital transformation, business and technical strategies, business outcomes, innovation efforts, adoption of artificial intelligence, and evaluation of critical resources. These forward-looking statements can be identified by the fact that they do not relate strictly to historical or current facts and may contain the words 'outlook,' 'potential,' 'believe,' 'anticipate,' 'expect,' 'intend,' 'plan,' 'predict,' 'estimate,' 'project,' 'will be,' 'will continue,' 'will likely result,' or other similar words and phrases or future or conditional verbs such as 'will,' 'may,' 'might,' 'should,' 'would,' or 'could' and the negatives of those terms. These forward-looking statements are based on current available operating, financial, economic and other information, and are not guarantees of future performance and are subject to risks, uncertainties and assumptions that are difficult to predict, including but not limited to, the following: our ability to achieve the expected benefits of our strategic plans and priorities and the success of other business initiatives; our ability to achieve profitability; our loan production volume; our ability to maintain an operating platform and management system sufficient to conduct our business; our ability to maintain warehouse lines of credit and other sources of capital and liquidity; our ability to effectively utilize artificial intelligence; impacts of cybersecurity incidents, cyberattacks, information or security breaches and technology disruptions or failures, of ours or of our third party vendors; the outcome of legal proceedings to which we are a party; our ability to reach a definitive settlement agreement related to the Cybersecurity Incident; adverse changes in macroeconomic and U.S residential real estate and mortgage market conditions, including changes in interest rates and changes in global trade policy and tariffs; changing federal, state and local laws, as well as changing regulatory enforcement policies and priorities; and other risks detailed in the "Risk Factors" section of loanDepot, Inc.'s Annual Report on Form 10-K for the year ended December 31, 2024, and Quarterly Reports on Form 10-Q as well as any subsequent filings with the Securities and Exchange Commission. Therefore, current plans, anticipated actions, and financial results, as well as the anticipated development of the industry, may differ materially from what is expressed or forecasted in any forward-looking statement. loanDepot does not undertake any obligation to publicly update or revise any forward-looking statement to reflect future events or circumstances, except as required by applicable law. About loanDepot: Since its launch in 2010, loanDepot (NYSE: LDI) has revolutionized the mortgage industry with digital innovations that make transacting easier, faster and less stressful for customers and originators alike. The company, which is licensed in all 50 states, helps its customers achieve the American dream of homeownership through a broad suite of lending and real estate services that simplify one of life's most complex transactions. loanDepot is also committed to serving the communities in which its team lives and works through a variety of local and national philanthropic efforts. LDI-IR
Business Wire
2 hours ago
- Business Wire
Polpharma Biologics and Fresenius Kabi Sign Licensing Agreement for Proposed Vedolizumab Biosimilar PB016
AMSTERDAM, ZUG, Switzerland & GDAŃSK, Poland--(BUSINESS WIRE)--Polpharma Biologics S.A. ('Polpharma Biologics') announces a global (except for Middle East & North Africa) licensing agreement with Fresenius Kabi for the commercialization of PB016, a proposed biosimilar to vedolizumab, an integrin receptor antagonist, (reference product: Entyvio®*), a biologic therapy indicated for moderate to severe ulcerative colitis and Crohn's disease. Under the terms of the agreement, Polpharma Biologics will lead development and manufacturing of PB016, while Fresenius Kabi will hold exclusive commercialization rights worldwide, excluding Middle East & North Africa. 'This partnership reinforces our mission to broaden access to high-quality biologics that improve patient outcomes globally,' said Konstantin Matentzoglu, Supervisory Board Member of Polpharma Biologics Group. 'Fresenius Kabi's deep commercialization experience and commitment to biosimilars make them an ideal partner for bringing PB016 to patients worldwide. Together, we are taking an important step toward addressing the rising burden of chronic inflammatory diseases.' The agreement builds on Polpharma Biologics' growing biosimilar portfolio and proven development capabilities. The company has previously brought forward multiple biosimilars — including ranibizumab and natalizumab — across global markets in partnership with leading pharmaceutical companies. This strategic collaboration strengthens both companies' commitments to expanding global access to affordable biologic medicines while supporting healthcare system sustainability. *Entyvio® is a registered trademark of Takeda. About Polpharma Biologics: Polpharma Biologics is an international biotechnology company with integrated operations in the European Union (EU), developing and manufacturing biosimilar medicines. Using patented solutions and state-of-the-art platform technologies, Polpharma Biologics develops biosimilar products to treat a range of conditions in major therapeutic areas. Programs at Polpharma Biologics start in cell line development and transition through technical and clinical development to commercial-scale production preparing drugs for future commercial partnerships with global pharmaceutical organizations. The expertise of Polpharma Biologics lies in the development and manufacture of medicines based on microbial and mammalian expression systems. With its cell line development center in the Netherlands and two centers of development and manufacturing in Poland, Polpharma Biologics creates growth and development opportunities for biotechnology specialists. Learn more at About Fresenius Kabi: As part of the global healthcare company Fresenius, Fresenius Kabi specializes in (bio)pharmaceuticals, medical technologies and nutrition products for critical and chronic conditions. The company's products, technologies, and services are used for the therapy and care of critically and chronically ill patients. With more than 41,000 employees and present in over 100 countries, Fresenius Kabi's expansive product portfolio focuses on providing access to high-quality and lifesaving medicines and technologies. For more information, please visit Important Note This press release is for informational purposes only and does not constitute promotional material for PB016 in Poland or any other jurisdiction. The commercialization of proposed vedolizumab biosimilar PB016 is solely the responsibility of Fresenius Kabi, the marketing authorization holder, in accordance with all applicable laws and regulations. Disclaimer This press release is issued from Polpharma Biologics Group and is intended to provide worldwide information to healthcare professionals, media and (potential) investors about our global business in relation to drug development and manufacturing expertise. Although Polpharma Biologics Group is not a public company as of this date, recipients should understand that this press release contains certain forward-looking statements (as defined in the U.S. Private Securities Litigation Reform Act of 1995). These statements involve inherent risks and uncertainties, and actual results may differ materially from those expressed or implied in the forward-looking statements. Factors that could cause actual results to differ materially include, but are not limited to, the approval and commercialization of the medicinal product, market reception, competition, changes in economic conditions and applicable laws, global regulatory developments, contractual risks and dependencies from third parties. Polpharma Biologics undertakes no obligation to update any forward-looking statements to reflect events or circumstances after the date of this press release. Moreover, Polpharma Biologics wishes to emphasize that this press release is for informational purposes only and shall not be construed as making any representation, warranties, or guarantees, either express or implied, regarding the potential approval, market reception, commercialization, or success of the medicinal product or any other product or therapy.
